Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Merck acquired Idenix Pharmaceuticals for $3.85B, a hepatitis C drug developer.
Merck took a $2.9 billion impairment charge on the hepatitis C drug uprifosbuvir inherited from the $3.85 billion Idenix acquisition, raising questions about…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Merck acquired Idenix Pharmaceuticals for $3.85B, a hepatitis C drug developer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Idenix Pharmaceuticals (this deal) | 2014 | $3.9B | 15 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2014 deals · Merck & Co. Inc. deals · Infectious Disease deals